Top

Journal of Assisted Reproduction and Genetics

Published in:

01-03-2012 | ASSISTED REPRODUCTION TECHNOLOGIES

Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial

Authors: Ensieh Shahrokh Tehraninejad, Maryam Hafezi, Arezoo Arabipoor, Elham Aziminekoo, Mohammad Chehrazi, Akram Bahmanabadi

Published in: Journal of Assisted Reproduction and Genetics | Issue 3/2012

Abstract

Purpose

To compare the efficacy of cabergoline (Cb2) and intravenous human albumin (HA) in the prevention of ovarian hyperstimulation syndrome.

Methods

In this randomized controlled trial study, 138 women who were at high risk for developing OHSS were randomly allocated into two groups. In Group one, 20 gr of HA 20% was infused over 1 h. Group two received 0.5 mg per day of Cb2 orally for 7 days, starting on oocyte pickup day. All patients were visited seven and 14 days after oocyte retrieval to determine early clinical or ultrasound evidence of OHSS.

Results

Moderate OHSS was observed in 33 versus 14 cases in the HA and Cb2 groups, respectively, which was significantly different. The number of severe OHSS cases in the HA group was significantly higher than in the Cb2 group (P < 0.001).

Conclusions

Prophylactic oral low dose cabergoline was more effective and less costly than intravenous human albumin in the prevention of OHSS in high-risk patients. (NCT01009567)

Available only for authorised users

Mathur R, Kailasam CH, Jenkins J. Review of the evidence base of strategies to prevent ovarian hyper stimulation syndrome. Hum Fertil. 2007;10(2):75–85.CrossRef

Shoham Z, Weissman A, Barasch A, Borenstein R, Schachter M, Insler V. Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilization program: a prospective, randomized, placebo-controlled study. Fertil Steril. 1994;62:137–42.PubMed

Isik AZ, Gokmen O, Zeyneloglu HB, Kara S, Keles G, Gulekli B. Intravenous albumin prevents moderate-severe ovarian hyperstimulation in-vitro fertilization patients: a prospective randomized and controlled study. Eur J Obstet Gynecol Reprod Biol. 1996;70:179–83.PubMedCrossRef

Gokmen O, Ugur M, Ekin M, Keles G, Turan C, Oral H. Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme:a prospective randomized placebo controlled study. Eur J Obstet Gynecol Reprod Biol. 2001;96:187–92.PubMedCrossRef

Ben-Chetrit A, Eldar-Geva Y, Gal M, Huerta M, Mimon T, Algur N, Diamant YZ, Margalioth EJ. The questionable use of albumin for the prevention of ovarian hyperstimulation syndrome in an IVF programme: a randomized placebo-controlled trial. Hum Reprod. 2001;16:1880–4.PubMedCrossRef

Isikoglu M, Berkkanoglu M, Senturk Z, Ozgur K. Human albumin does not prevent ovarian hyperstimulation syndrome in assisted reproductive technology program: a prospective randomized placebo-controlled double blind study. Fertil Steril. 2007;88(4):982–5.PubMedCrossRef

Costabile L, Unfer V, Manna C, Gerli S, Rossetti D, Di Renzo GC. Use of intramuscular progesterone versus intravenous albumin for the prevention of ovarian hyperstimulation syndrome. Gynecol Obstet Invest. 2000;50:182–5.PubMedCrossRef

Bellver J, Muñoz EA, Ballesteros A, Soares SR, Bosch E, Simón C, Pellicer A, Remohí J. Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study. Human Reprod. 2003;18(11):2283–8.CrossRef

Chen CD, Chao KH, Yang JH, Chen SU, Ho HN, Yang YS. Comparison of coasting and intravenous albumin in the prevention of ovarian hyperstimulation syndrome. Fertil Steril. 2003;80(1):86–90.PubMedCrossRef

10.

Venetis CA, Kolibianakis EM, Toulis KA, Goulis DG, Papadimas I, Tarlatzis BC. Intravenous albumin administration for the prevention of severe ovarian hyperstimulation syndrome: a systematic review and metaanalysis. Fertil Steril. 2011;95(1):188–96.PubMedCrossRef

11.

Gómez R, Soares SR, Busso C, Garcia-Velasco JA, Simón C, Pellicer A. Physiology and pathology of ovarian hyperstimulation syndrome. Semin Reprod Med. 2010;28(6):448–57.PubMedCrossRef

12.

Gomez R, Gonzalez-Izquierdo M, Zimmermann RC, Novella-Maestre E, Alonso-Muriel I, Sanchez-Criado J. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2 dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology. 2006;147(11):5400–11.PubMedCrossRef

13.

Saylan A, Arioz DT, Koken T, Dilek H, Saylan F, Yilmazer M. Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam. Acta Obstet Gynecol Scand. 2010;89(5):292–9.CrossRef

14.

Alvarez C, Alonso-Muriel I, García G, Crespo J, Bellver J, Simón C, Pellicer A. Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Hum Reprod. 2007;22(12):3210–4.PubMedCrossRef

15.

Carizza C, Abdelmassih V, Abdelmassih S, Ravizzini P, Salgueiro L, Salgueiro PT, Jine LT, Nagy P, Abdelmassih R. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod BioMed Online. 2008;17(6):751–5.PubMedCrossRef

16.

Sohrabvand F, Ansaripour S, Bagheri M, Shariat M, Jafarabadi M. Cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive technologies outcome in high risk patients. Int J Fertil Steril. 2009;3(1):35–40.

17.

Soliman BS. Cabergoline vs intravenous albumin or combination of both for prevention of the early onset ovarian hyperstimulation syndrome. Middle East Fertil Soc J. 2011;16:56–60.CrossRef

18.

Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv. 1989;44:430–40.PubMedCrossRef

19.

Hwang JL, Lin YH, Soew KM. Failure of cabergoline to prevent severe ovarian hyperstimulation syndrome in patients with extremely high estradiol levels. Int J Gynaecol Obstet. 2010;108(2):159–60.PubMedCrossRef

20.

Youssef MA, van Wely M, Hassan MA. Review Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis. Hum Reprod Update. 2010;16(5):459–66.PubMedCrossRef

Title: Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial
Authors: Ensieh Shahrokh Tehraninejad
Maryam Hafezi
Arezoo Arabipoor
Elham Aziminekoo
Mohammad Chehrazi
Akram Bahmanabadi
Publication date: 01-03-2012
Publisher: Springer US
Published in: Journal of Assisted Reproduction and Genetics / Issue 3/2012
Print ISSN: 1058-0468
Electronic ISSN: 1573-7330
DOI: https://doi.org/10.1007/s10815-011-9708-4

At a glance: The STEP trials

Springer Medicine

Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2012

When ONE is the not-so-loneliest number!

Dipeptide forms of glycine support mouse preimplantation embryo development in vitro and provide protection against high media osmolality

Oocyte cryopreservation in a patient with sickle cell disease prior to hematopoietic stem cell transplantation: first report

Elevated day 3 FSH/LH ratio: a marker to predict IVF outcome in young and older women

Live birth from oocytes cryopreserved with slow-freezing protocol and thawed after 6 years of storage

Comments on the AZFc markers used for screening of Yq microdeletions